Viridian Therapeutics Inc (VRDN) – Company Profile and SWOT Analysis

Viridian Therapeutics Inc (VRDN) – Company Profile & SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

Viridian Therapeutics Inc (Viridian), formerly miRagen Therapeutics, focuses on the discovery and development of medicines for serious and rare diseases. The company’s major products in development are VRDN-001 and VRDN-003, which are aimed at treating thyroid eye disease (TED), and a portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, for autoimmune diseases. The company’s lead product candidate VRDN-001 is an intravenous humanized monoclonal antibody targeting IGF-1R, and VRDN-003 for subcutaneous administration, both aimed at treating thyroid eye disease (TED). The company develops novel RNA-based therapeutics, with a core focus on therapeutic antibodies and their roles in diseases. Viridian is headquartered in Waltham, Massachusetts, the US.

Scope

• Detailed information on Viridian Therapeutics Inc required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Viridian Therapeutics Inc in the form of a SWOT analysis

• An in-depth view of the business model of Viridian Therapeutics Inc including a breakdown and examination of key business segments

• News about Viridian Therapeutics Inc, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Viridian Therapeutics Inc and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Viridian Therapeutics Inc as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Viridian Therapeutics Incs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Ionis Pharmaceuticals Inc

Immunovant Inc

Dicerna Pharmaceuticals Inc

Horizon Therapeutics Ltd

Arrowhead Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Viridian Therapeutics Inc - Key Facts

Viridian Therapeutics Inc - Key Employees

Viridian Therapeutics Inc - Key Employee Biographies

Viridian Therapeutics Inc - Major Products and Services

Viridian Therapeutics Inc - History

Viridian Therapeutics Inc - Company Statement

Viridian Therapeutics Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Viridian Therapeutics Inc - Business Description

R&D Overview

Viridian Therapeutics Inc - Corporate Strategy

Viridian Therapeutics Inc - SWOT Analysis

SWOT Analysis - Overview

Viridian Therapeutics Inc - Strengths

Viridian Therapeutics Inc - Weaknesses

Viridian Therapeutics Inc - Opportunities

Viridian Therapeutics Inc - Threats

Viridian Therapeutics Inc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Viridian Therapeutics Inc, Medical Equipment, Deals By Year, 2018 to YTD 2024

Viridian Therapeutics Inc, Medical Equipment, Deals By Type, 2018 to YTD 2024

Viridian Therapeutics Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Feb 16, 2024: Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

Jan 08, 2024: Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

Oct 30, 2023: Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing

Sep 25, 2023: Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors

Sep 08, 2023: Viridian Therapeutics : Appointments

May 09, 2023: Viridian Therapeutics reports first quarter 2023 financial results and provides corporate update

Apr 12, 2023: Viridian Therapeutics : Departure of Directors or Certain Officers

Mar 01, 2023: Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

Feb 06, 2023: Viridian Appoints Scott Myers as President and Chief Executive Officer

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Viridian Therapeutics Inc, Key Facts

Viridian Therapeutics Inc, Key Employees

Viridian Therapeutics Inc, Key Employee Biographies

Viridian Therapeutics Inc, Major Products and Services

Viridian Therapeutics Inc, History

Viridian Therapeutics Inc, Subsidiaries

Viridian Therapeutics Inc, Key Competitors

Viridian Therapeutics Inc, Ratios based on current share price

Viridian Therapeutics Inc, Annual Ratios

Viridian Therapeutics Inc, Annual Ratios (Cont…1)

Viridian Therapeutics Inc, Interim Ratios

Viridian Therapeutics Inc, Medical Equipment, Deals By Year, 2018 to YTD 2024

Viridian Therapeutics Inc, Medical Equipment, Deals By Type, 2018 to YTD 2024

Viridian Therapeutics Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Viridian Therapeutics Inc, Performance Chart (2019 – 2023)

Viridian Therapeutics Inc, Ratio Charts

Viridian Therapeutics Inc, Medical Equipment, Deals By Year, 2018 to YTD 2024

Viridian Therapeutics Inc, Medical Equipment, Deals by Type, 2018 to YTD 2024

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports